Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Clinical and observational research has shown that GLP-1 medications are associated with reduced alcohol cravings, lower consumption, and decreased risk of alcohol-related disorders GLP-1 use is already widespread in the U.S
Proof of Past Efforts: Many Aetna plans require you to prove that youve tried and failed to lose weight through other methods, like a documented diet and exercise program, for a certain period (often 3-6 months)
MEDVi offers both medications, and your physician can recommend switching if your clinical response warrants it
This projects approval around Q3 2027 under an optimistic priority-review scenario, or Q1Q2 2028 under standard review
